binds with high affinity to 11␤-hydroxylase because the basic nitrogen in etomidate's imidazole ring forms a coordination bond with the heme iron at the enzyme's active site (31) . In carboetomidate, etomidate's basic nitrogen has been replaced with a -CH moiety to eliminate the ability to form this coordination bond and reduce affinity for 11␤-hydroxylase.
Because of carboetomidate's favorable characteristics, we hypothesize that it might be a suitable replacement for etomidate that would allow the safe administration of multiple boluses or prolonged continuous infusions. Such drugs are predicted not to impact the normal adrenocortical response to sepsis that is thought to play an important role in suppressing the accompanying proinflammatory cytokine storm (32) (33) (34) (35) . As a test of this hypothesis, we defined the impact of single and multiple doses of carboetomidate and etomidate on plasma levels of ACTH, corticosterone, and cytokines in rats challenged with Escherichia coli lipopolysaccharide (LPS) to determine whether these two agents differentially affect the inflammatory response to endotoxemia.
MATERIALS AND METHODS
Animals. This study was approved by the Subcommittee on Research Animal Care at the Massachusetts General Hospital, Boston, MA. The care and handling of the animals was in accord with National Institutes of Health guidelines for ethical animal research. Adult male Sprague-Dawley rats (320 -370 g) were purchased from Charles River Laboratories (Wilmington, MA) with preimplanted femoral venous catheters. Rats were individually caged with controlled temperature (21 Ϯ 2°C) and light-dark cycles (7 AM to 7 PM) in the Massachusetts General Hospital Center for Comparative Medicine animal care facility with food and water provided at libitum.
Drugs and Chemicals. Carboetomidate was synthesized by Aberjona Laboratories (Beverly, MA) as previously described (30) . Etomidate was from Bachem Americas (Torrance CA). LPS from E. coli serotype 055:B5 and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO).
General Procedure. All animal studies were begun at 8:30 AM to minimize diurnal variations. Each rat received supplemental oxygen (100%, 2 L/min) through a port in the chamber throughout the experiment. After weighing, rats were allowed to acclimate for 2 hrs to restriction within a 3-inch diameter, 9-inch long acrylic chamber with a tail exit port. A sublethal dose of LPS (1 mg/kg dissolved in 1 mL of saline) was administered through the femoral venous catheter.
For single anesthetic dose studies (n ϭ 5 rats/group), a single dose of etomidate (2 mg/kg in DMSO), carboetomidate (14 mg/kg in DMSO), or DMSO vehicle alone (as a control) was administered through the femoral catheter immediately after injection of LPS followed by a 1-mL saline flush. These anesthetic doses are twice the respective ED50s for loss of righting reflexes in rats and produce similar durations of hypnosis (30, 36) . The concentrations of etomidate and carboetomidate were 2.85 mg/mL and 20 mg/ mL, respectively, which maintained the volume of DMSO vehicle injected into each rat at 0.7 mL/kg. Rats in the control group similarly received 0.7 mL/kg DMSO but without anesthetic.
For multiple anesthetic dose studies (n ϭ 5 rats/group), etomidate (2 mg/kg in DMSO), carboetomidate (14 mg/kg in DMSO), or DMSO vehicle alone was administered through the femoral catheter immediately after injection of LPS. Anesthetic in DMSO (or DMSO vehicle alone) was readministered every 15 mins for a total of eight doses (i.e., 15, 30, 45, 60, 75, 90 , and 105 mins post-LPS injection). For these studies, the concentrations of etomidate and carboetomidate were 11.4 mg/mL and 80 mg/mL in DMSO, respectively. This maintained the total volume of DMSO vehicle injected into each rat at 1.4 mL/kg. Rats in the control group similarly received 1.4 mL/kg DMSO but without anesthetic. No rats died during our experiments. However, in the multiple anesthetic dose study, a single rat in the carboetomidate group had a plasma interleukin-6 (IL-6) concentration before LPS injection that was an order of magnitude higher than the average of all other rats and the IL-6 concentration failed to increase after LPS injection. Because this suggested the presence of a pre-existing infection perhaps related to placement of the femoral venous line, all data from this rat were eliminated from analyses.
For both single and multiple anesthetic dose studies, blood samples (400 L) were collected through the femoral catheter immediately before LPS administration and 2, 15, 30, 60, 120, 160, and 300 mins post-LPS injection. This blood was replaced with 1 mL of saline. On collection, blood samples were mixed with EDTA (3 mg) and centrifuged at 1530 g for 15 mins. The resultant plasma was stored at Ϫ80°C until assayed.
Plasma ACTH and corticosterone concentrations in all blood draws were measured individually for each animal using an enzymelinked immunosorbent assay with kits from MD Bioproducts (St. Paul, MN) and Immunodiagnostics Systems (Fountain Hills, AZ), respectively. Plasma cytokine concentrations were measured for each animal at time points 0 min, 30 mins, 60 mins, 120 mins, and 300 mins post-LPS injection using a MILLPLEX MAP Rat Cytokine/Chemokine Panel (Millipore, St. Charles, MO).
Statistical Analysis. All data are reported as mean Ϯ SE. Statistical analyses were done using Prism version 5.0 for Macintosh (GraphPad Software, Inc., La Jolla, CA). To compare differences in plasma corticosterone or cytokine concentrations among groups at each time point, a repeated measures two-way analysis of variance was performed where the factors were time after LPS administration and drug group followed by a Bonferroni posttest. For all statistical analyses, p values of Ͻ.05 were considered to indicate statistical significance.
RESULTS

Anesthetic Modulation of Plasma ACTH Concentrations After LPS Injection: Single and Multiple Anesthetic Dose Studies
In single and multiple anesthetic dose studies, injection of LPS produced a rapid increase in plasma ACTH concentrations in all three groups (i.e., control, etomidate, and carboetomidate groups). Respective peak plasma ACTH concentrations in the single and multiple dose studies were 350 Ϯ 114 pg/mL and 330 Ϯ 58 pg/mL in the control groups, 540 Ϯ 75 pg/mL and 470 Ϯ 123 pg/mL in the etomidate groups, and 430 Ϯ 148 pg/mL and 430 Ϯ 116 pg/mL in the carboetomidate groups 30 -120 mins post-LPS injection (Fig. 2) . After peaking, plasma ACTH concentrations in all groups remained elevated throughout the remainder of the 5-hr experiment. In each study, we detected no significant difference at any time point in plasma ACTH concentrations among the three groups.
Anesthetic Modulation of Plasma Corticosterone Concentrations After LPS Injection
Single Anesthetic Dose Studies. In all three groups, plasma corticosterone concentrations increased after LPS injection and peaked 120 mins post-LPS injection (control group: 510 Ϯ 27 ng/mL, etomidate group: 490 Ϯ 51 ng/mL, and carboetomidate group: 480 Ϯ 42 ng/mL; Fig.  3A ). At no time point was the plasma corticosterone concentration in the carboetomidate group significantly different from the corresponding one in the control group. However, at two time points before reaching a peak (30 mins and 60 mins post-LPS injection), plasma corticosterone concentrations in the etomidate group were significantly lower than the corresponding ones in the carboetomidate group.
Multiple Anesthetic Dose Studies. In the control and carboetomidate groups, plasma corticosterone concentrations increased after LPS injection, peaking 120 mins post-LPS injection (350 Ϯ 34 ng/mL and 410 Ϯ 52 ng/mL, respectively; Fig. 3B ) and at no time point were plasma corticosterone concentrations significantly different between the two groups. Conversely, in the etomidate group, plasma corticosterone concentrations initially decreased significantly (from 110 Ϯ 28 ng/mL before LPS injection to 32 Ϯ 10 ng/mL 15 mins post-LPS injection and 27 Ϯ 7 ng/mL 30 mins post-LPS injection) and then failed to increase significantly above the pre-LPS injection value until the final time point of our study. As such, the plasma corticosterone concentrations in the etomidate group were significantly lower than the corresponding ones in the control and carboetomidate groups at all time points between 30 mins and 180 mins post-LPS injection.
Anesthetic Modulation of Plasma Cytokine Concentrations After LPS Injection
Single Anesthetic Dose Studies. In all three groups, plasma tumor necrosis factor-␣, IL-1␤, IL-6, and IL-10 concentrations increased by at least tenfold after LPS injection and peaked by 120 mins post-LPS injection (Fig. 4A) . There was no statistically significant difference in the plasma concentration of any cytokine in either anesthetic group vs. that in the control group at any time point.
Multiple Anesthetic Dose Studies. In all three groups, plasma tumor necrosis factor-␣, IL-1␤, IL-6, and IL-10 concentrations increased by at least tenfold after LPS injection and peaked by 120 mins post-LPS injection (Fig. 4B) . There was no statistically significant difference at any time point in plasma tumor necrosis factor-␣ concentrations among the three groups. However, the peak plasma concentration of IL-1␤ was significantly higher in the etomidate group than in the control or carboetomidate groups (500 Ϯ 200 pg/mL vs. 130 Ϯ 20 pg/mL and 210 Ϯ 70 pg/mL, respectively). Similarly, the peak plasma concentration of IL-6 was significantly higher in the etomidate group than in the control or carboetomidate groups (90 Ϯ 14 ng/mL vs. 46 Ϯ 6 ng/mL and 52 Ϯ 5 ng/mL) and remained higher 300 mins post-LPS injection. In Figure 2 . Time-dependent changes in plasma adrenocorticotropic hormone concentrations after administration of lipopolysaccharide (1 mg/kg at 0 min) and either (A) a single dose of anesthetic or vehicle (also at time 0) or (B) eight doses of anesthetic or vehicle (one dose every 15 mins beginning at 0 min and ending at time 105 mins). Each etomidate and carboetomidate dose was 2 mg/kg and 14 mg/kg, respectively, which is twice the ED50 for loss of righting reflexes in rats (30, 36) . Vehicle was dimethyl sulfoxide. Each data point is the mean Ϯ SEM of four or five animals. Adrenocorticotropin hormone, ACTH. . Each etomidate and carboetomidate dose was 2 mg/kg and 14 mg/kg, respectively, which is twice the ED50 for loss of righting reflexes in rats (30, 36 
DISCUSSION
This is the first study of the pyrrole etomidate analog carboetomidate in a model of sepsis. It defined the effects of carboetomidate on plasma ACTH, corticosterone, and cytokine concentrations and compared them with the effects of etomidate and vehicle alone after an LPS challenge in rats. Our results reveal that carboetomidate and etomidate differentially affect the inflammatory response that results from LPS administration. This difference was most pronounced in studies using multiple anesthetic doses administered over a prolonged period of time because etomidate significantly reduced plasma corticosterone concentrations and increased peak plasma concentrations of the proinflammatory cytokines IL-1␤, IL-6, and the anti-inflammatory cytokine IL-10, whereas carboetomidate only increased plasma concentrations of IL-10.
Several animal models of sepsis have been used to replicate either the signs and symptoms or the laboratory findings observed in human sepsis (37) . These include bacterial infusion models, polymicrobial peritonitis models, and endotoxin models. Each model replicates certain aspects of clinical sepsis but also has its own limitations. For example, bacterial infusion models are not exactly analogous to clinical situations where there is commonly a focus on infection providing continuous dissemination of bacteria that colonize and replicate (38, 39) . Bacterial peritonitis models closely resemble the clinical scenario of sepsis after bowel perforation, but the model has wide variability in terms of the host inflammatory and physiological responses and the level of bacteremia and mortality rates (40, 41) . We chose the endotoxin model in the present study because the model is highly reproducible and mimics the hyperinflammatory response that often occurs in patients in septic shock while acknowledging that it differs from clinical sepsis because it lacks an infectious focus and produces larger and more transient cytokine responses.
Numerous cytokines have been identified that play important roles in the pathophysiology of sepsis (42) . The proinflammatory cytokines tumor necrosis factor-␣, IL-1␤, and IL-6 have been shown to both modulate and to be modulated by the hypothalamic-pituitaryadrenal axis (32, (43) (44) (45) (46) . Such crosstalk suggests that drugs known to inhibit adrenocortical function (e.g., etomidate, but not carboetomidate) might alter the production of these cytokines. In contrast, IL-10 possesses strong anti-inflammatory properties that may counteract some of the actions of these proinflammatory cytokines and improve survival (45) .
Our results demonstrate that etomidate inhibits LPS-stimulated corticosterone production in vivo. After LPS injection, a single intravenous etomidate dose significantly reduced plasma corticosterone concentrations (relative to vehicle controls) for 60 -120 mins. This duration of adrenocortical suppression is shorter than that observed in humans (20, 47, 48) , which may reflect the presence of an aliesterase found in rat blood that rapidly metabolizes etomidate (49) . With multiple etomidate doses, plasma corticosterone concentrations initially decreased after LPS administration. This likely reflects the combined effects of metabolism of existing plasma corticosterone along . Each etomidate and carboetomidate dose was 2 mg/kg and 14 mg/kg, respectively, which is twice the ED50 for loss of righting reflexes in rats (30, 36) with inhibition of new corticosterone synthesis during prolonged etomidate administration. Etomidate reduced plasma corticosterone concentrations without impacting the ACTH response to LPS injection, consistent with etomidate's known direct inhibitory action on 11␤-hydroxylase activity (18, 50) .
Carboetomidate's affect on the adrenocortical response to an LPS challenge was significantly less than that of etomidate and not different from that of vehicle alone even when multiple doses were administered over a nearly 2-hr time period. This implies that carboetomidate does not significantly inhibit 11␤-hydroxylase activity and is consistent with our previous observation that carboetomidate does not suppress the adrenocortical response to exogenously administered ACTH (30) .
In addition to differences between etomidate and carboetomidate with respect to the adrenocortical response to LPS injection, we also observed differences in their impact on cytokine production because peak plasma IL-1␤ and IL-6 concentrations were significantly higher after administration of etomidate vs. carboetomidate (or vehicle control). These differences between etomidate and carboetomidate may relate to their differential effects on adrenocortical function because glucocorticoids reduce proinflammatory cytokine synthesis. For example, dexamethasone administration reduces the serum IL-1 concentration of mice challenged with LPS (51) and hydrocortisone infusion reduces plasma levels of IL-6 in patients in septic shock (34) . Similarly, reducing glucocorticoid synthesis by either surgical adrenalectomy (32) or pharmacologic adrenalectomy with mifepristone (44) increases plasma concentrations of IL-6 after LPS administration.
Although there have been few clinical studies defining the effects of etomidate on cytokine production, they suggest a link between etomidate-induced adrenocortical suppression and increased proinflammatory cytokine production. A study by Jameson et al (52) showed that compared with thiopentone, etomidate reduced plasma cortisol concentrations and increased plasma IL-6 concentrations in women undergoing hysterectomies. In pediatric patients with meningococcal sepsis, a study by Den Brinker et al (53) showed that plasma IL-6 concentrations were inversely related to the cortisol: ACTH ratios and increased in patients who had received etomidate. A study by Yeager et al (54) found that perioperative hydrocortisone replacement therapy administered to patients who received etomidate for cardiac surgery dose-dependently reduced postoperative plasma IL-6 concentrations.
In summary, our studies demonstrate that carboetomidate has lesser effects than etomidate on the adrenocortical and proinflammatory cytokine responses to LPS administration. This suggests that unlike etomidate, carboetomidate may be useful as an anesthetic maintenance agent in patients with sepsis.
